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Genome editing in primary cells and in vivo using
viral-derived Nanoblades loaded with Cas9-sgRNA
ribonucleoproteins
Philippe E. Mangeot1, Valérie Risson2, Floriane Fusil1, Aline Marnef3, Emilie Laurent1, Juliana Blin 1,
Virginie Mournetas4, Emmanuelle Massouridès 4, Thibault J.M. Sohier 1, Antoine Corbin1, Fabien Aubé5,
Marie Teixeira6, Christian Pinset4, Laurent Schaeffer2, Gaëlle Legube3, François-Loïc Cosset1, Els Verhoeyen1,7,
Théophile Ohlmann1 & Emiliano P. Ricci 1,5
Programmable nucleases have enabled rapid and accessible genome engineering in eukar-
yotic cells and living organisms. However, their delivery into target cells can be technically
challenging when working with primary cells or in vivo. Here, we use engineered murine
leukemia virus-like particles loaded with Cas9-sgRNA ribonucleoproteins (Nanoblades)
to induce efﬁcient genome-editing in cell lines and primary cells including human
induced pluripotent stem cells, human hematopoietic stem cells and mouse bone-marrow
cells. Transgene-free Nanoblades are also capable of in vivo genome-editing in mouse
embryos and in the liver of injected mice. Nanoblades can be complexed with donor DNA for
“all-in-one” homology-directed repair or programmed with modiﬁed Cas9 variants to mediate
transcriptional up-regulation of target genes. Nanoblades preparation process is simple,
relatively inexpensive and can be easily implemented in any laboratory equipped for cellular
biology.
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Targeted genome editing tools, such as meganucleases(MGN), zinc-ﬁnger nucleases (ZFN), transcriptionactivator-like effector nucleases (TALENs) and more
recently the clustered regularly interspaced short palindromic
repeats (CRISPR) have revolutionized most biomedical research
ﬁelds. Such tools allow to precisely edit the genome of eukaryotic
cells by inducing double-stranded DNA (dsDNA) breaks at
speciﬁc loci. Relying on the cell endogenous repair pathways,
dsDNA breaks can then be repaired by non-homologous end-
joining (NHEJ) or homology-directed repair (HDR) allowing the
removal or insertion of new genetic information at a desired
locus.
Among the above-mentioned tools, CRISPR-Cas9 is cur-
rently the most simple and versatile method for genome engi-
neering. Indeed, in the two-component system, the bacterial-
derived nuclease Cas9 (for CRISPR-associated protein 9)
associates with a single-guide RNA (sgRNA) to target a com-
plementary DNA sequence and induce a dsDNA break1.
Therefore, by the simple modiﬁcation of the sgRNA sequence,
users can specify the genomic locus to be targeted. Consistent
with the great promises of CRISPR-Cas9 for genome engi-
neering and gene therapy, considerable efforts have been made
in developing efﬁcient tools to deliver the Cas9 and the sgRNA
into target cells ex vivo either by transfection of plasmids
coding for the nucleases, transduction with viral-derived vec-
tors coding for the nucleases or by direct injection or electro-
poration of Cas9-sgRNA complexes into cells.
Here, we have designed Nanoblades, a protein-delivery vector
based on friend murine leukemia virus (MLV) that allows the
transfer of Cas9-sgRNA ribonucleoproteins (RNPs) to cell lines
and primary cells in vitro and in vivo. Nanoblades deliver the
ribonucleoprotein cargo in a transient and rapid manner without
delivering a transgene and can mediate knock-in in cell lines
when complexed with a repair template. Nanoblades can also be
programmed with modiﬁed Cas9 proteins to mediate transient
transcriptional activation of targeted genes.
Results
Cas9-sgRNA RNP delivery through MLV virus-like particles
(VLPs). Assembly of retroviral particles relies on the viral
structural Gag polyprotein, which multimerizes at the cell
membrane and is sufﬁcient, when expressed in cultured cells, to
induce release of VLPs into the cell supernatant2. When Gag is
coexpressed together with a fusogenic viral envelope, pseudo-
typed VLPs are produced that lack a viral genome but still retain
their capacity to fuse with target cells and deliver the Gag
protein`into their cytoplasm. As previously investigated3,4, we
took advantage of the structural role of Gag and designed an
expression vector coding for the MLV Gag polyprotein fused, at
its C-terminal end, to a ﬂag-tagged version of Streptococcus
pyogenes Cas9 protein (Gag::Cas9, Fig. 1a). The two fused pro-
teins are separated by a proteolytic site which can be cleaved by
the MLV protease to release the Flag-tagged Cas9 (Fig. 1a). By
cotransfecting HEK-293T cells with plasmids coding for Gag::
Cas9, Gag-Pro-Pol, a sgRNA, and viral envelopes, fusogenic VLPs
are produced and released in the culture medium (herein
described as Nanoblades). Biochemical and imaging analysis of
puriﬁed particles (Supplementary Figure 1a, 1b, 1c and 1d)
indicates that Nanoblades (150 nm) are slightly larger than wild-
type MLV (Supplementary Figure 1b) but sediment at a density
of 1.17 g/ml (Supplementary Figure 1c) as described for MLV
VLPs5. As detected by western blot, Northern blot, mass-spec-
trometry, and deep-sequencing, Nanoblades contain the Cas9
protein and sgRNA (Supplementary Figure 1 and 2 and Supple-
mentary Data 1). In addition to Gag, Cas9 and envelope proteins,
mass-spectrometry analysis of Nanoblades identiﬁed several
cellular proteins, mostly membrane-associated proteins (Supple-
mentary Figure 2a and Supplementary Data 1). Interestingly,
the packaging of sgRNA depends on the presence of the Gag::
Cas9 fusion protein, since Nanoblades produced from cells that
only express the Gag protein fail to incorporate detectable
amounts of sgRNA (Supplementary Figure 1d). Furthermore,
Cas9-dependent loading of the sgRNA within Nanoblades is not
limited by the efﬁciency of the interaction between the Cas9 and
the sgRNA, since expressing an optimized version of the sgRNA
that improves binding to Cas96 does not appear to increase
sgRNA levels within puriﬁed VLPs (Supplementary Figure 1d
see sgRNA(F+E)).
To assess for Cas9-sgRNA RNP delivery efﬁciency in target
cells and induction of genomic dsDNA breaks, we designed
Nanoblades with a sgRNA targeting the 45S rDNA loci. Human
45S rDNA genes are present in hundreds of tandem repeats
across ﬁve autosomes, locate in the nucleolus and are transcribed
exclusively by RNA polymerase (Pol) I7. Using immunoﬂuores-
cence microscopy, it is therefore possible to follow the occurrence
of dsDNA breaks at rDNA loci with single-cell resolution
by monitoring the nucleolus using the nucleolar marker RNA
Pol I and the well-established dsDNA break-marker, histone
variant γ-H2AX8, that localizes at the nucleolar periphery after
dsDNA break induction within rDNA9. U2OS (osteosarcoma
cell line) cells transduced for 24 h with Nanoblades programmed
with a sgRNA targeting rDNA display the typical γ-H2AX
distribution at the nucleolar periphery with RNA Pol I, indicative
of rDNA breaks, whilst cells transduced with Nanoblades with
control sgRNAs do not (Fig. 1b, top panel). Interestingly, this
distribution of γ-H2AX at the nucleolar periphery can be
observed as early as 4 h after transduction in 60% of cells with
a maximum effect observed at 16 h after transduction, where
almost 100% of observed cells display this γ-H2AX distribution
(Fig. 1b, bottom panel and quantiﬁcation below). In comparison,
only 60% of cells transfected with a plasmid coding for Cas9
and the sgRNA display the perinucleolar γ-H2AX/RNA Pol I
localization 24 h after transfection. Similar results were obtained
in human primary ﬁbroblasts with more than 85% cells
displaying this distribution after 16 h (Supplementary Figure 1e).
These results suggest that Nanoblade-mediated delivery of the
Cas9-sgRNA RNP is both efﬁcient and rapid in cell lines and
primary human cells. To further conﬁrm these results, we
designed and dosed Nanoblades (by ELISA assay using anti-Cas9
antibodies) programmed with a sgRNA widely used in the
literature10 that targets the human EMX1 gene to induce dsDNA
cleavage at a single locus. HEK-293T cells were then transduced
with increasing amounts of Nanoblades and gene editing was
measured from the bulk population 48 h after transduction
(Fig. 1c). Under these conditions, we observed a dose-dependent
effect of Nanoblades ranging from 35% of EMX1 (at 4 pmol of
Cas9) editing to 77% of editing at the highest dose (20 pmol)
of Cas9 (Fig. 1c).
Because Nanoblades carry cellular proteins from producer
cells in addition to Cas9 (Supplementary Data 1), we tested
whether these proteins could also be delivered to recipient
cells. For this, we over-expressed the ﬁreﬂy luciferase in
producer cells and collected Nanoblades targeting EMX1 from
the supernatant. Luciferase-loaded Nanoblades were then
used to transduce HEK293T cells for 24 h. Cells were then
washed twice in PBS and incubated in fresh medium for 4, 8,
24, and 48 h. Luciferase activity was measured at each time
point, as well as in input Nanoblades (Supplementary
Figure 2c). As observed, we could detect a mild luciferase
signal (4–6% of input) at 4 and 8 h upon transduction.
However, the signal rapidly faded at 24 h (2% of input) and
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was almost undetectable at 48 h (Supplementary Figure 2c).
In addition to the ectopically expressed ﬁreﬂy luciferase, we
also investigated transmission of the CD81 cell-surface protein,
which is highly expressed in HEK293T producer cells and
is present in Nanoblades as revealed by mass spectrometry
(Supplementary Data 1). HepG2 cells, a hepatic cell line that
lacks CD81 expression11, were transduced for 24 h with
Nanoblades targeting EMX1 and then washed twice with PBS
before monitoring CD81 residual signal immediately after
the washes or 8 and 48 h after incubation with fresh medium
(Supplementary Figure 2d). As observed, even though CD81
was very abundant at the cell surface of producer cells
and completely absent in recipient cells (Supplementary
Figure 2d, left and middle panels), we could only detect a
mild CD81 signal immediately after transduction (see Supple-
mentary Figure 2d, right panel). Later time points (8 and 48 h)
did not show any speciﬁc CD81 labeling in recipient HepG2
cells. The impact of cellular proteins delivered by Nanoblades
into recipient cells appears therefore limited and restricted to
a short time frame.
Taken together, our results indicate that Nanoblades can
be efﬁciently used to mediate genome editing in a rapid and
dose-dependent manner with limited impact on the proteome
of target cells.
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Fig. 1 Nanoblade-mediated genome editing. a Scheme describing the MLV Gag::Cas9 fusion and the Nanoblade production protocol based on the
transfection of HEK-293T cells by plasmids coding for Gag-Pol, Gag::Cas9, VSV-G, BaEVRLess, and the sgRNA. b Top panel, immunoﬂuorescence analysis
of γ-H2AX (green), RNA polI (red) in U2OS cells 8 h after being transduced with control Nanoblades or with Nanoblades targeting ribosomal DNA genes.
Bottom panel, quantiﬁcation of γ-H2AX and RNA polI colocalization foci in U2OS cells at different times after Nanoblades transduction or after classical
DNA transfection methods (n= 3, error bars correspond to standard deviation). c Dose response of Nanoblades. HEK-293T cells were transduced with
increasing amounts of Nanoblades targeting human EMX1 (n= 1 displayed). The exact amount of Cas9 used for transduction was measured by dot blot (in
gray). Genome editing was assessed by Sanger sequencing and Tide analysis (in red)
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Nanoblades-mediated genome editing in primary cells. Gen-
ome editing in primary cells and patient-derived pluripotent cells
represents a major interest both for basic science and ther-
apeutical applications. However, primary cells are often refractory
to DNA transfection and other gene delivery methods. Because
Nanoblades were capable of efﬁcient delivery of functional Cas9-
sgRNA RNPs into primary ﬁbroblasts, we tested whether they
were effective in other primary cells for genome editing. To this
aim, Nanoblades targeting EMX1 were used to transduce human-
induced pluripotent stem cells (hiPSCs). Genome editing at the
EMX1 locus was assessed in the bulk cellular population 48 h after
transduction by deep-sequencing of the EMX1 locus (Fig. 2a, left
panel). As observed, Nanoblades were capable of mediating 67%
genome editing at the EMX1 locus in hiPSCs. Notably, hiPSCs
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treated with EMX1 Nanoblades maintained constant levels of
pluripotency markers compared to control cells (Fig. 2a, right
panel) thus indicating that their multipotent status did not appear
to be affected.
Similarly to hiPSCs, mouse bone marrow (BM) cells can be
collected and differentiated in vitro into various hematopoietic
cell types, such as macrophages (bone marrow-derived macro-
phages or BMDMs) and dendritic cells. Efﬁcient genome editing
of speciﬁc genes in BM cells would therefore allow for the
corresponding pre-existing protein to be degraded during
differentiation and obtain a functional knockout. To test this
hypothesis, BM cells obtained from GFP transgenic mice12 were
transduced with Nanoblades programmed with a sgRNA
targeting the GFP coding sequence. 6 h after transduction, cells
were washed and incubated in presence of macrophage colony-
stimulating factor (MCSF) for 1 week. After this, cells were
collected to monitor GFP levels by ﬂuorescence microscopy,
FACS and genome editing by T7 endonuclease assay (Fig. 2b).
We consistently obtained close to 75% reduction of GFP
expression as measured by FACS analysis and around 60–65%
genome editing at the GFP locus as measured by T7 endonuclease
assays (Fig. 2b). Importantly, genome editing through Nano-
blades did not affect the capacity of BMDMs to respond to LPS
as their cytokine expression remains identical to that of
untreated control cells (Fig. 2b bottom right panel). Nanoblades
can therefore be used to inactivate genes in BM cells and study
their function in differentiated cells. To further complement
these results, we compared the efﬁciency of Nanoblades to that
of recombinant Cas9-sgRNA RNP electroporation in targeting
an endogenous gene in primary mouse BM cells. For this,
Nanoblades or Cas9-sgRNA RNPs programmed to target the Fto
gene were used, respectively, to transduce or electroporate
primary BM cells freshly extracted from mice. As a control,
Nanoblades or Cas9-sgRNA RNPs programmed to target human
EMX1 were also tested in HEK293T cells. In both cases, the
efﬁciency of genome editing was assessed 24 h after transduction
or electroporation. As observed (Fig. 2c), both Nanoblades and
Cas9-sgRNA electroporation mediate efﬁcient genome editing
in HEK293T at 71% (Nanoblades) and 44% (Electroporation)
of editing efﬁciency at the EMX1 locus. Interestingly, in primary
BM cells, while Nanoblades achieve highly efﬁcient genome
editing of the Fto locus (up to 76% as measured by TIDE13
analysis), Cas9 electroporation was much less efﬁcient at both
conditions that we tested (1350 and 1680 V) yielding a mild
but visible signal in the T7 endonuclease assay which was
nevertheless below the detection limit for TIDE analysis.
Interestingly both protocols (Nanoblades and protein electro-
poration) did not have an important impact on cell viability 24 h
after Cas9 delivery (Supplementary Figure 2e).
Nanoblades efﬁciency was also investigated in human cells that
represent a major interest in research and gene therapy like
human primary hepatocytes and human hematopoietic stem cells
(HSCs) that both have the capacity to colonize and regenerate
fully functional tissues. For both these cell types, Nanoblades
programmed with two sgRNAs targeting the human Myd88
gene were prepared and achieved signiﬁcant cleavage efﬁciencies,
as revealed by ﬂanking PCR assays (Fig. 2d). Interestingly, HSCs
are difﬁcult to transduce with classic VSV-G pseudotyped
lentiviral vectors (LVs) because they lack the LDL receptor14,
a limitation that can be alleviated by the use of the baboon
retroviral envelope glycoprotein (BaEV)15. This prompted us to
equip Nanoblades with both BaEV and VSV G-envelopes for
these cells and ﬁnally in all our study as the combination of both
envelopes improved Cas9 delivery in most cells (Supplementary
Figure 6a and b). As observed, Nanoblades were also able to
induce genome editing in these cells (50% genome editing based
on T7 endonuclease assay, Fig. 2d) thus expanding the catalog
of primary cells that can be edited using Nanoblades.
Taken together, our results indicate that Nanoblades are an
efﬁcient delivery system to induce rapid and effective genome
editing in murine and human primary cells of high therapeutic
value that are notoriously difﬁcult to transfect.
“All-in-one” Nanoblades for homology directed repair. Precise
insertion of genetic material (also known as Knock-in) using
CRISPR-Cas9 can be achieved through HDR. This occurs when a
donor DNA template with sequence homology to the region
surrounding the targeted genomic locus is provided to cells
together with the Cas9-sgRNA RNP. Based on a previous ﬁnding
showing that retroviral-particles can be complexed with DNA in
the presence of polybrene to allow for virus-dependent DNA
transfection16, we tested whether Nanoblades could be directly
complexed with a DNA template to mediate HDR in target cells.
To test this approach, Nanoblades programmed to target a locus
close to the AUG start codon of the human DDX3 gene were
complexed to a single-stranded DNA oligomer bearing the
FLAG-tag sequence ﬂanked with 46 nucleotide (nt) homology
arms corresponding to the region surrounding the start-codon of
DDX3 (Fig. 3a, left panel). HEK293T were transduced with these
“All-in-one” Nanoblades and passed 6 times before assessing
HDR efﬁciency in the bulk cellular population both by PCR and
by Flag-immunoprecipitation followed by western-blotting (using
a DDX3 and FLAG-antibody). As observed (Fig. 3a, right panel),
cells transduced with “All-in-one” Nanoblades showed incor-
poration of the FLAG-tag at the DDX3 locus both genetically
and at the level of protein expression (Fig. 3a right panel, see
Flag-IP elution and Genotyping panels). In parallel, single-cell
Fig. 2 Genome editing in primary cells transduced with Nanoblades. a Left panel, editing efﬁciency at the EMX1 locus (measured by high-throughput
sequencing on the Illumina Miseq platform) of human-induced pluripotent stem cells (hiPSCs) transduced with Nanoblades targeting human EMX1 (n= 3).
Right panel, expression of pluripotency markers measured by qPCR in control cells and cells transduced with Nanoblades targeting EMX1 (n= 3). b Left and
middle panels, ﬂuorescence microscopy and FACS analysis of GFP expressing BMDMs transduced at the bone marrow stage (day 0 after bone marrow
collection) with control Nanoblades or Nanoblades targeting the GFP-coding sequence (n= 3). Right top panel, T7 endonuclease assay against the GFP
sequence from Nanoblades-treated BMDMs. Right bottom panel, cytokine expression levels (measured by qPCR) in untreated or Nanoblade-treated cells
upon LPS stimulation (n= 4). c T7 endonuclease assay against mouse Fto or human EMX1 genomic sequences ampliﬁed by PCR from primary mouse bone
marrow cells transduced with Nanoblades or electroporated with recombinant Cas9-sgRNA RNPs. For bone marrow cells, two electroporation settings
were tested. Lanes numbered #1–#3 correspond to biological replicates. Editing efﬁciencies were calculated by TIDE13 analysis of the Sanger sequencing
electropherograms for each PCR amplicon d Left panel, excision of a 160 bp DNA fragment of MYD88 using Nanoblades. Middle panel PCR results
obtained in human primary hepatocytes transduced with Nanoblades. Right-panel (top), FACS analysis of CD34+ cells puriﬁed from human cord-blood.
Bottom, genome editing at the MYD88 locus assessed by PCR in untreated and Nanoblades-treated CD34+ cells. Error bars in all ﬁgures correspond to
standard deviation
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clones were derived from the Flag-DDX3 bulk population and
tested for Flag incorporation by PCR. As shown (Fig. 3a left
bottom panel), 12 out of 20 isolated clones displayed incor-
poration of the Flag-sequence at the DDX3 locus thus suggesting
a knock-in efﬁciency of more than 50% of cells using “all-in-one”
Nanoblades.
Knock-in assisted by “All-in-one” Nanoblades was also
obtained at the AAVS1 locus which has been described as a safe
harbor for transgene insertion17. For this we designed a dsDNA
template of 4 kb bearing the puromycin resistance gene with
homology arms to the AAVS1 locus. After transduction of HEK-
293T cells with Nanoblades complexed with this template using
polybrene, single-cell-derived clones were selected with puromy-
cin. Out of 1 × 105 transduced cells, we obtained 47 puromycin-
resistant clones (Supplementary Figure 3b, c and d). A PCR-assay
revealed that 42 out of 47 puromycin-resistant clones tested had
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the puromycin cassette inserted at the AAVS1 locus (Supple-
mentary Figure 3d).
Taken together, our results show that Nanoblades can be
used for the precise insertion of genetic material through HDR
both with ssDNA and dsDNA donor DNA template and no
requirement for any transfection reagent.
Nanoblades confer low off-target genome-editing. A major
concern related to the use of CRISPR/Cas9-mediated gene editing
are the potential off-target effects that can occur at genomic loci
that are similar in sequence to the original target. Interestingly,
several reports have shown that transient delivery of the Cas9-
sgRNA complex by injection or RNP transfection generally leads
to reduced off-target effects as compared to constitutive expres-
sion of Cas9 and sgRNA from DNA transfection experiments18.
Since Nanoblades deliver the Cas9-sgRNA complex in a dose-
dependent and transient fashion, we tested whether they could
also lead to reduced off-target effects when compared to classical
DNA transfection. For this, we developed an approach similar to
that described by Fu and colleagues19 by creating a series of HEK-
293T reporter cell lines transduced with different versions of a
GFP transgene bearing silent point mutations located in the
sgRNA target site (Fig. 3b, right panel). These cells were either
transfected with plasmids coding for Cas9 and the sgRNA tar-
geting the GFP or transduced with Nanoblades programmed with
the same sgRNA. 96 h after transfection/transduction, cells were
collected and GFP expression was monitored by FACS (Fig. 3b,
left panel). As expected, GFP expression from cells bearing the
wild-type GFP sequence (No Mismatch) was efﬁciently repressed
both after Nanoblades transduction (close to 80% repression) and
DNA transfection (close to 60% repression) (Fig. 3b, left panel
“No Mismatch”). When two mismatches were introduced in the
target site, Nanoblades were no longer able to efﬁciently repress
GFP expression (20% compared to control) while GFP expression
from transfected cells was still reduced to levels similar to that of
the GFP bearing a perfect match with the sgRNA. Interestingly,
the presence of three or four mismatches completely abolished
GFP editing in Nanoblades-treated cells while cells transfected
with the Cas9 and sgRNA plasmids still displayed a mild inhi-
bition of GFP expression (Fig. 3b see 3 and 4 Mismatches).
To complement these results, we further tested for genomic
off-target effects using the well-characterized sgRNA targeting
human EMX1. Off-targets for this sgRNA have been extensively
studied using T7 endonuclease assays and high-throughput
sequencing approaches10. We PCR-ampliﬁed the EMX1 locus
and one of the previously described EMX1 genomic off-target loci
occurring at the intron of MFAP110 in cells treated for 72 h with
Nanoblades programmed with the EMX1 sgRNA or transfected
with a DNA construct coding for Cas9 and the EMX1 sgRNA.
We then assessed genome-editing on each sample by high-
throughput sequencing (Fig. 3c)13. Editing at the on-target site
was efﬁcient in Nanoblade-treated cells (75% in average) and
to a less extent in cells transfected with the DNA coding for
Cas9 and the sgRNA (53% in average) (Fig. 3c, left panel). As
expected, small INDELs (insertions and deletions) occurred close
to the expected Cas9 cleavage site located 3nt upstream the
PAM sequence both in Nanoblades treated and in DNA-
transfected cells (Supplementary Figure 4). Surprisingly, in spite
of the higher editing efﬁciency at the on-target site, we could not
detect any signiﬁcant editing at the MFAP1 off-target site in
Nanoblades-treated cells (Fig. 3c, right panel). In contrast, cells
transfected with the DNA coding for Cas9 and the sgRNA
displayed signiﬁcant editing (close 6%) at the off-target site
(Fig. 3c, right panel) and had INDELs at the expected cut site
(Supplementary Figure 4).
Taken together, our results indicate that similarly to other
protocols that lead to transient delivery of the Cas9-sgRNA RNP,
Nanoblades display low off-target effects.
Targeted transcriptional activation through Nanoblades. Hav-
ing shown efﬁcient genome editing using Nanoblades loaded with
the catalytically active Cas9, we tested whether Nanoblades could
also deliver Cas9 variant proteins for applications, such as tar-
geted transcriptional activation. To this aim, we fused the Cas9-
derived transcriptional activator (SP-dCas9-VPR)20 to Gag from
MLV and expressed the fusion protein in producer cells together
with a control sgRNA or different combinations of sgRNAs tar-
geting the promoter region of human Titin (TTN) as previously
described20 (Fig. 3d, left panel). Nanoblades loaded with SP-
dCas9-VPR were then incubated with MCF-7 cells and induction
of TTN measured by quantitative RT-PCR (normalized to
GAPDH expression). As observed (Fig. 3d, right panel), when
two different sgRNAs were used in combination, TTN tran-
scription was stimulated from 50 to 200 fold compared to the
control situation. Interestingly, when combining the four differ-
ent sgRNAs in a single VLP, we obtained up to 400-fold tran-
scription stimulation of TTN after 4 h of transduction. Our
results therefore suggest that in spite of the large molecular size of
the SP-dCas9-VPR (predicted at 224 kDa alone and 286 kDa
when fused to MLV Gag), neither its encapsidation within VLPs
nor its delivery and function within target cells are impaired. The
use of Cas9 variants could therefore expand the toolbox of
potential applications of Nanoblades in immortalized and pri-
mary cells.
Fig. 3 “All-in-one” Nanoblades for knock-in experiments and assessment of Nanoblades off-target activity. a Left panel, Nanoblades targeting human DDX3
close to its start codon were complexed with a donor ssDNA bearing homology arms to the targeted locus and a Flag-tag sequence in the presence of
polybrene. HEK293T cells were then transduced with these “All-in-one” Nanoblades. After cell ampliﬁcation, a fraction of cells were collected to extract
genomic DNA and total proteins while the remaining cells were cultured to obtain single-cell clonal populations. Right panel, insertion of the Flag-tag in
HEK-293T cells transduced with “all-in-one” Nanoblades complexed with increasing amounts of donor ssDNA was assessed by Flag-immunoprecipitation
followed by western-blot using anti-ﬂag or anti-DDX3 antibodies in the input and Flag-immunoprecipitation elution fractions. Flag insertion was also
assessed by PCR using a forward primer in the ﬂag-sequence and a reverse primer in the DDX3 locus (Orientation PCR assay) or using primers ﬂanking the
Flag sequence (Insertion PCR assay). Bottom panel, Flag-insertion in 20 different single-cell-derived clones was assessed by PCR using primers ﬂanking
the Flag-sequence. b Left panel, off-target monitoring in immortalized mouse macrophages stably expressing GFP transgenes bearing silent mutations in
the region targeted by the sgRNA. Right panel, cells were transfected with plasmids coding for Cas9 and the sgRNA or transduced with Nanoblades. GFP
expression was measured by FACS 72 h after transfection/transduction (n= 3). c Left and right panels, gene-editing at the EMX1 on-target site and the
MFAP1 intronic off-target site measured by high-throughput sequencing in untreated cells (control cells) and cells transduced with EMX1 Nanoblades
(Nanoblades) or transfected with plasmids coding for Cas9 and the EMX1 sgRNA (DNA transfection) (n= 3). Statistical signiﬁcance of the Nanoblades and
DNA transfection comparison at the on-target site was computed using a two-tail Student test. d Left panel, position of sgRNAs targeting the promoter of
TTN and VLPs with different combination of sgRNAs produced for the experiment. Right-panel, TTN mRNA expression levels (normalized to Control) as
measured by qPCR in MCF7 transduced with VLPs (n= 3). Error bars in all ﬁgures correspond to standard deviation
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Nanoblades-mediated transduction of mouse zygotes. CRISPR-
Cas9 has been extensively used to generate transgenic animals
through microinjection of zygotes with DNA coding for Cas9 and
the sgRNA or with the synthetic sgRNA and a Cas9 coding
mRNA or directly with the preassembled Cas9-sgRNA RNP21.
However, some of these options usually require injection into the
pronucleus or the cytoplasm of zygotes, which can signiﬁcantly
impact their viability. Moreover, in some species, pronucleus and
even cytoplasmic microinjection can be technically challenging.
Because Nanoblades are programmed to fuse with their target
cells, we reasoned that they could also transduce murine zygotes
without requiring intracellular microinjection. To test this
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hypothesis, VLPs loaded with the mCherry protein (instead of
Cas9) were produced and injected in the perivitelline space of
mouse zygotes (Fig. 4a, top panel). Embryos were harvested 80 h
after injection (blastocyst stage) and visualized by ﬂuorescence
microscopy, showing mCherry protein delivery within embryo
cells (Fig. 4a, right panel).
Nanoblades programmed with a sgRNA targeting the ﬁrst
exon of the tyrosinanse (Tyr) gene previously described in ref. 22
were produced and injected in the perivitelline space of mouse
zygotes. This particular sgRNA was speciﬁcally designed to
target a HinfI restriction site in the Tyr gene that should be
disrupted upon dsDNA cleavage and NHEJ repair22 (Fig. 4b).
80 h after injection, blastocysts were harvested and genomic DNA
extracted to monitor genome-editing by PCR ampliﬁcation
followed by T7 endonuclease assay or HinfI restriction. As
observed (Fig. 4d), 16 out of 40 blastocysts were positive for
genome-editing at the Tyr gene both for the T7 endonuclease
and the HinfI restriction assays. Interestingly, three blastocysts
(#11, #20, and #33) appeared to bear complete Tyr editing as
we could not detect any residual HinfI restriction products
(Fig. 4d). In the remaining 13 blastocysts that were positive for
genome editing at the Tyr locus, we observed different editing
efﬁciencies thus arguing for variable levels of mosaicism between
individuals (Fig. 4d). Interestingly, injection of Nanoblades in the
perivitelline was not associated with embryo mortality as we
did not obtain any signiﬁcant difference in survival rates between
injected and non-inject embryos (Fig. 4c). To further validate
these results, we produced Nanoblades programmed with two
sgRNAs targeting the Tyr locus (see Fig. 4e bottom scheme) that
were injected in the perivitelline space of single-cell embryos,
which were then implanted into pseudopregnant females and
carried to term. In this case, ﬁve out of eight F0 mice obtained
carried detectable Tyr editing both at the phenotype and genotype
level as assayed by PCR ampliﬁcation of the Tyr locus from
genomic DNA extracted from the ﬁngers of each animal (Fig. 4e).
Interestingly, one of the two fully albino mice carried a complete
deletion of the DNA segment between the two sgRNA-targeted
loci in all tested cells (as assayed by Sanger sequencing of the bulk
PCR product and Sanger sequencing of single clone PCR
fragments (Fig. 4e bottom panels)). The remaining F0 mice that
displayed a partial Tyr disruption phenotype had an editing
efﬁciency ranging from 11% up to 78% of all Tyr alleles (Fig. 4e
see table). Sanger sequencing of individual PCR clones ampliﬁed
from these mice indicated that one of the two sgRNAs (sgRNA1)
was more efﬁcient in inducing INDELs (Fig. 4e bottom scheme).
Moreover, we also detected some degree of mosaicism within
each individual mouse (with the exception of mouse #3 which
had complete bi-allelic excision of the Tyr sequence between the
two target loci) with at least two types of INDELs detected in
mice 7 and 8 (Fig. 4e, see genomic alignment scheme). This,
however, is very similar to the degree of mosaicism found in other
approaches22,23. Taken together, these results validate the use of
Nanoblades to generate transgenic mice upon perivitelline
injection of single-cell embryos.
To further conﬁrm the ability of Nanoblades to mediate
genome-editing in mouse embryos and transmission of the edited
locus to the offspring, we designed a sgRNA targeting the loxP
sequence that could mimic the action of the Cre recombinase by
removing a loxP ﬂanked cassette (Supplementary Figure 5, left
panel). These Nanoblades were ﬁrst tested in primary BM cells
derived from R26R-EYFP transgenic mice bearing a single-copy
of the YFP transgene under control of a “lox-stop-lox” cassette24
(Supplementary Figure 5, top right panel). Nanoblades were then
injected in the perivitelline space of heterozygous R26R-EYFP 1-
cell embryos which were then implanted into pseudopregnant
females and carried to term. In this case, 1 out of 14 founder
animals was YFP positive under ultraviolet (UV) light and
displayed efﬁcient excision of the “lox-stop-lox” cassette as
conﬁrmed by PCR25 (Supplementary Figure 5, bottom left panel).
Consistent with our previous results, the F1 progeny obtained
after mating the loxed F0 mouse with a wild-type mouse
contained the “loxed” version of the YFP allele and displayed YFP
expression in tails and muscle ﬁbers (Supplementary Figure 5,
bottom right panel), indicating efﬁcient transmission of the loxed
allele from the F0 founder to its progeny.
Taken together, Nanoblades can represent a viable alternative
to classical microinjection experiments for the generation of
transgenic animals, in particular for species with fragile embryos
or with poorly visible pronuclei.
In vivo editing of Hpd in the liver of tyrosinaemic FRG mice.
Hereditary tyrosinemia type I (HT1) is a metabolic disease caused
by disruption of fumarylacetoacetate hydrolase (Fah), which is an
enzyme required in the tyrosine catabolic pathway. Fah-/- mice
recapitulate many phenotypic characteristics of HT1 in humans,
such as hypertyrosinemia and liver failure and have to be
treated with nitisinone for their survival. Disruption of hydro-
xyphenylpyruvate dioxigenase (HPD, the enzyme targeted by
nitisinone) through hydrodynamic tail vein injection in Fah-/-
mice was recently shown to restore their survival in the absence of
nitisinone thanks to the selective advantage of Hpd negative
hepatocytes26. We therefore reasoned that Nanoblades could
represent a non-invasive method to inactivate the Hpd gene
in NRG (NODFah-/-/Rag2-/-/Il2rg-/-) mice27. To this aim, we
designed a sgRNA directed against the fourth exon of Hpd, which
should disrupt the reading frame through the INDELs caused
by NHEJ (see Methods section for the sequence). Nanoblades
directed against Hpd or against human EMX1 (control) were
introduced in NRG mice through retro-orbital injection (Fig. 5a).
Upon injection, mice were weaned off nitisinone until they
reached a 20% loss of their body weight, in which case nitisinone
was subsequently administered punctually. Two weeks after
injection, all mice injected with Nanoblades targeting Hpd dis-
played detectable editing in the liver (between 7% and 13%
Fig. 4 Generation of transgenic mice using Nanoblades. a Left panel, scheme describing injection of mCherry VLPs or Nanoblades in the perivitelline space
of mouse 1-cell embryos. Right panel, ﬂuorescence microscopy of mouse blastocysts injected with mCherry VLPs at the single-cell stage. b Scheme of the
design strategy to target the mouse Tyr locus (adapted from ref. 22). Upon editing and NHEJ repair, the HinfI restriction site becomes inactive. c Survival
rates of injected embryos at two-cell, blastocyst, and newborn stage (the latter obtained from experiments presented in Supplementary ﬁgure 5). d T7
endonuclease (top panel) and HinfI restrictions (bottom panel) assays on PCR fragments ampliﬁed from the Tyr locus of Control or Nanoblades-injected
embryos. e Top left panel, photographs of F0 mice generated from embryos injected with Nanoblades programmed with two sgRNAs targeting the Tyr
locus. Top-right panel, phenotype, editing efﬁciency (as measured by TIDE analysis of the Sanger-sequencing electropherograms) and the main INDEL type
as detected by Sanger sequencing of individual PCR clones. Bottom-panel, alignment of individual PCR clones obtained from the Tyr locus of F0 mice
against the mouse mm10 genome indicating the main observed INDELs in chimeric mice (mouse #4, #7, and #8) and total excision of the Tyr sequence
between the sgRNA1 and sgRNA2 targeting loci for the complete albino mouse (mouse #3). The Sanger sequencing electropherogram from the bulk PCR
amplicon obtained from mouse #3 indicates complete editing at both targeted sites
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efﬁciency, Fig. 5b). On the contrary, no editing was detected in
control (uninjected) mice or in mice injected with Nanoblades
targeting human EMX1 (Fig. 5b). Similar results were obtained
4 weeks post-injection where all mice injected with Nanoblades
targeting Hpd displayed genome editing in the liver (Fig. 5b).
Furthermore, genome-editing occurred in a homogenous
fashion across the liver as shown by T7 endonuclease assay from
biopsies recovered from three different lobes of a single ani-
mal (Fig. 5b, bottom panel). In contrast, editing in other
organs, such as spleen was weak or not detectable (Fig. 5b).
Interestingly, we observed a small overall increase in editing
levels at 4 weeks post-injection compared to 2 weeks post-
injection suggesting that cells with Hpd editing could have
a selective advantage over non-edited cells (Fig. 5b compare
middle and bottom panel). Because we did not monitor
genome editing earlier than 2 weeks post injection, we cannot
rule out that a similar selective advantage of edited cells
might have occurred during this incubation time. Nevertheless,
based on the weak increase of the editing efﬁciency observed
between 2 and 4 weeks after injection, we do not expect this
selective advantage to signiﬁcantly improve the observed editing
efﬁciency during the ﬁrst 2 weeks after injection. Importantly,
Nanoblades injection was not associated with any signs of
morbidity.
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Fig. 5 Inactivation of Hpd in the liver of tyrosinaemic FRG mice. a Scheme of the experimental approach to target the liver of FRG mice. b T7 endonuclease
assay to monitor genome editing at the Hpd gene in immortalized mouse macrophages and in the liver or spleen of injected mice. Samples were quantiﬁed
using a Tapestation chip
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Discussion
Genome editing should ideally be achieved in a fast and precise
fashion to limit toxicity and possible off-target effects due to a
sustained expression of effectors. In this regard, extensive efforts
have been recently described to vehicle Cas9-sgRNA RNPs in
cultured cells and in vivo by non-coding material including
Nanocarriers28, optimized transfection reagents18, or lentivirus-
derived particles29.
This work describes and characterizes VLPs to efﬁciently
vectorize the CRISPR-Cas9 system into primary cells, embryos,
and animals. These non-coding agents—we called herein Nano-
blades—incorporate the Cas9 endonuclease into their internal
structure. The molecular basis of this technology is the fusion of
Cas9 from Streptococcus pyogenes to Gag from MLV. Expressed
with other components of viral assembly and construct encoding
gRNA(s), this molecule can bind sgRNAs into producer cells,
forms RNP complexes and cohabit with Gag and Gag-Pol within
particles. We indeed show that robust packaging of sgRNAs into
Nanoblades depends on their interaction with Gag::Cas9 (Sup-
plementary Figure 1d).
When compared to other methods of delivery such as lipo-
fection or electroporation, Nanoblades were more efﬁcient and
rapid in inducing dsDNA breaks both in immortalized U2OS
cells, primary ﬁbroblasts (Fig. 1b, Supplementary Figure 1e).
Nanoblades are also functional in primary cells that are
known to be difﬁcult to transfect and transduce using classical
delivery methods, such as human iPS cells, human CD34+ and
primary mouse bone-marrow cells (Fig. 2) reaching efﬁciencies
comparable or even superior to other recent methods30,31, such as
Cas9-sgRNA ribonucleoprotein electroporation (Fig. 2c), together
with low off-target effects (Fig. 3b and c). Furthermore, Nano-
blades achieve genome editing in a dose-dependent manner
(Fig. 1c). Beyond delivery of Cas9-sgRNA complexes, we also
show that Nanoblades can be complexed with DNA repair tem-
plates to mediate homologous recombination-based knock-in
cultured cells in the absence of any transfection reagent. Our
results also validate the use of Nanoblades in vivo for generating
transgenic mice upon embryo injection in the perivitelline space
(Fig. 4 and Supplementary Figure 5) or in the liver of injected
animals (Fig. 5). Although, other recent methods for in vivo
genome editing of zygotes and animals have reached higher
editing rates22,23,32–34, Nanoblades represent a viable, inexpen-
sive, and accessible alternative that can still beneﬁt from further
improvements.
Similarly to other cell-derived particles (including most viral
vectors), Nanoblades incorporate RNAs and proteins from pro-
ducer cells that could be responsible for the transmission of
undesired effects. Mass spectrometry analysis of the content of
Nanoblades revealed that plasma membrane terms were parti-
cularly enriched, which is consistent with the vesicular nature
of Nanoblades (Supplementary Figure 2a and Supplementary
Data 1). As previously described for retroviral-VLPs35, char-
acterization of the RNA content revealed that Nanoblades contain
thousands of individual cellular mRNA species, most of these
being encapsidated stochastically, in proportion to their abun-
dance in the producer cell. We found that transcripts over-
expressed for production purposes (GAG, VSV-G, etc.) represent
<0.4% of Nanoblades RNAs (Supplementary Figure 2b) sup-
porting the notion that their delivery to recipient cells is marginal.
Conﬁrming this observation, transfer of cellular proteins loaded
in Nanoblades from producer cells to recipient cells appears to be
minimal and restricted to a short time window between 8 and
24 h after transduction (Supplementary Figure 2c and d). While
we cannot exclude the fact that VLPs may be responsible for some
cellular responses, depending on the nature of recipient cells,
efﬁcient doses of Nanoblades were globally harmless for most
primary cells we tested and in injected animals. In our effort to
exploit the retroviral nature of Nanoblades, we explored diverse
pseudotyping options (Supplementary Figure 6) and ﬁnally
focused on the use of an original mixture of two envelopes (VSV-
G plus BRL), a recipe that we have optimized (Supplementary
Figure 6) and which systematically displayed the best cleavage
results in most recipient cells. Depending on the cellular target, it
may be possible to pseudotype Nanoblades with envelopes from
Measles virus36, inﬂuenza virus37, or other targeting systems38,39
to restrict or improve Cas9 delivery to certain cell types (Sup-
plementary Figure 6a).
Next generation Nanoblades may also beneﬁt from the con-
tinual evolutions of Cas9-derivatives that can support fusion with
Gag from MLV (Fig. 3) and could be adapted to other gene-
editing targetable nucleases like Cpf1 nucleases40 or even the
latest generation of programmable base editors41. We also noted
that Nanoblades can be engineered to accommodate other pro-
teins/RNAs in addition to Cas9-RNPs and serve as multi-
functional agents. Nanoblades capable of delivering both Cas9-
RNPs and a reverse-transcribed template that can serve for
reparation by homologous-recombination could therefore be
envisioned. Furthermore, multiple sgRNAs can be incorporated
within Nanoblades thus allowing gene excisions or multiple genes
to be targeted. Multiplexing of sgRNAs may also allow the
introduction of an additional sgRNA targeting a speciﬁc gene that
will allow selection of cells efﬁciently edited by Nanoblade-
mediated CRISPR42.
This versatility allows any laboratory equipped with BSL2
facilities to generate its own batches of particles. Beyond cell lines,
our VLP-based technique provides a powerful tool to mediate
gene editing in hiPSCs and primary cells including macrophages,
human hematopoietic progenitors and primary hepatocytes. We
have shown that Nanoblades injection into the perivitelline space
of mouse-zygotes was particularly harmless for the recipient cells,
since none of the injected zygotes were affected in their devel-
opment after treatment. Generation of transgenic animals upon
perivitelline space injection of VLPs could be adapted to other
species, including larger animals for which the number of zygotes
is limited. Finally, we achieved signiﬁcant gene-editing in the liver
of injected adult mice with no consequences on their viability.
Nanoblades, could therefore represent an interesting route for the
delivery of Cas9 in vivo to inactivate gene expression but also
used in combination with other viral delivery tools carrying a
donor DNA template (such as Adeno-associated virus (AAV)) to
perform in vivo HDR experiments as recently shown32.
Considering the examples provided in our work, we believe
that the Nanoblade technology will facilitate gene editing in
academic laboratories working with primary cells and could
represent a viable alternative for therapeutical purposes and the
rapid generation of primary cell-types harboring genetic diseases,
humanized-liver mouse models and transgenic animal models.
Methods
Plasmids. SP-dCas9-VPR was a gift from George Church (Addgene plasmid
#63798). Lenti CRISPR was a gift from F. Zhang (Addgene plasmid #49535).
The GagMLV-CAS9 fusion was constructed by sequential insertions of PCR-
ampliﬁed fragments in an eukaryotic expression plasmid harboring the human
cytomegalovirus early promoter (CMV), the rabbit Beta-globin intron and
polyadenylation signals. The MA-CA-NC sequence from Friend MLV (Accession
Number: M93134) was fused to the MA/p12 protease-cleavage site (9 aa) and
the Flag-nls-spCas9 ampliﬁed from pLenti CRISPR.
Cell culture. Gesicle Producer 293T (Clontech 632617), U2OS cells, and primary
human ﬁbroblasts (Coriell Institute, GM00312) were grown in DMEM supple-
mented with 10% fetal calf serum (FCS).
hiPSCs were obtained and cultured as described in ref. 43.
Bone marrow-derived macrophages (BMDMs) were differentiated from BM
cells obtained from wild-type C57BL/6 mice. Cells were grown in DMEM
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supplemented with 10% FCS and 20% L929 supernatant containing MCSF as
described in ref. 44. Macrophages were stimulated for the indicated times with LPS
(Invivogen) at a ﬁnal concentration of 100 ng/ml.
CD34+-cell sample collection, isolation, and transduction. Cord blood (CB)
samples were collected in sterile tubes containing the anti-coagulant, citrate-
dextrose (ACD, Sigma, France) after informed consent and approval was obtained
by the institutional review board (Centre international d’infectiologie (CIRI), Lyon,
France) according to the Helsinki declaration. Low-density cells were separated
over, Ficoll-Hypaque. CD34+ isolation was performed by means of positive
selection using magnetic cell separation (Miltenyi MACs) columns according to the
manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). Purity
of the selected CD34+ fraction was assessed by FACS analysis with a phycoery-
thrin (PE)-conjugated anti-CD34 antibody (Miltenyi Biotec, Bergisch Gladbach,
Germany) and exceeded 95% for all experiments. Human CD34+ cells were
incubated for 18–24 h in 24-well plates in serum-free medium (CellGro, CellGenix,
Germany) supplemented with human recombinant: SCF (100 ng/ml), TPO (20 ng/
ml), Flt3-L (100 ng/ml) (Myltenyi, France). 5 × 104 prestimulated CD34+ cells
were then incubated with nanoblades in 48-well plates in serum-free medium.
sgRNA design and sequences (+PAM). sgRNAs targeting MYD88, DDX3, GFP,
Hpd, Fto, Tyr, and the LoxP sequence were designed using CRISPRseek45.
Human AAVS1: 5′ ACCCCACAGTGGGGCCACTAggg 3′
Human DDX3: 5′ AGGGATGAGTCATGTGGCAGtgg 3′
Human EMX1: 5′ GAGTCCGAGCAGAAGAAGAAggg 3′
Human MYD88 #1: 5′ GAGACCTCAAGGGTAGAGGTggg 3′
Human MYD88 #2: 5′ GCAGCCATGGCGGGCGGTCCtgg 3′
Human rDNA: 5′ CCTTCTCTAGCGATCTGAGagg 3′
Human TTN -169: 5′ CCTTGGTGAAGTCTCCTTTGagg 3′
Human TTN -252: 5′ ATGTTAAAATCCGAAAATGCagg 3′
Human TTN -326: 5′ GGGCACAGTCCTCAGGTTTGggg 3′
Human TTN -480: 5′ ATGAGCTCTCTTCAACGTTAagg 3′
Mouse Fto: 5′ CATGAAGCGCGTCCAGACCGcgg 3′
Mouse Hpd: 5′ GAGTTTCTATAGGTGGTGCTGGGTGggg 3′
Mouse Tyr: 5′ GGGTGGATGACCGTGAGTCCtgg 3′ obtained from Chen et al. 22
Mouse Tyr: 5′ AACTTCATGGGTTTCAACTGcgg 3′ obtained from Yoon et al. 23
Mouse Tyr: 5′ ATGGGTGATGGGAGTCCCTGcgg 3′ this study
LoxP: 5′ CATTATACGAAGTTATATTAagg 3′
GFP: 5′ CGAGGAGCTGTTCACCGGGGtgg 3′
Production of Nanoblades. Nanoblades were produced from transfected gesicles
producer 293T cells plated at 5 × 106 cells/10 cm plate 24 h before transfection with
the JetPrime reagent (Polyplus). Plasmids encoding the GagMLV-CAS9 fusion
(1.7 µg), Gag-POLMLV (2.8 µg), gRNA expressing plasmid(s) (4.4 µg), VSV-G
(0.4 µg), the Baboon Endogenous retrovirus Rless glycoprotein (BaEVRless)15
(0.7 µg) were cotransfected and supernatants were collected from producer cells
after 40 h. For production of serum-free particles, medium was replaced 24 h after
transfection by 10 ml of Optimem (Gibco) supplemented with
penicillin–streptomycin. Nanoblade-containing medium was clariﬁed by a short
centrifugation (500 × g 5 min) and ﬁltered through a 0.8 µm pore-size ﬁlter before
ultracentrifugation (1h30 at 96,000 × g). Pellet was resuspended by gentle agitation
in 100 µl of cold 1X PBS. Nanoblades were classically concentrated 100-fold. X-
Nanoblades referred as Nanoblades loaded with gRNA(s) targeting the x-gene.
To dose Cas9 packaged into particles, Nanoblades or recombinant Cas9 (New
England Biolabs) were diluted in 1X PBS and serial dilutions were spotted onto a
Nitrocellulose membrane. After incubation with a blocking buffer (nonfat Milk 5%
w/v in TBST), membrane was stained with a Cas9 antibody (7A9-3A3 clone, Cell
signaling) and revealed by a secondary anti-mouse antibody coupled to horseradish
peroxidase. Cas9 spots were quantiﬁed by Chemidoc touch imaging system
(Biorad).
Transduction procedure. Transductions with Nanoblades were performed in a
minimal volume to optimize cell/particles interactions for at least 2 h before sup-
plementing with fresh medium. When speciﬁed, polybrene was used at a ﬁnal
concentration of 4 µg/ml in the transduction medium. After dosing Cas9 amount
in each Nanoblades preparation, we typically used 10 pmol of encapsidated Cas9
for 1 × 105 adherent cells.
sgRNA in vitro transcriptions. sgRNAs were in vitro transcribed using the EnGen
sgRNA Synthesis kit, S. pyogenes (New England Biolabs; E3322S) following the
manufacturer’s protocol with the following oligonucleotides:
Human EMX1: 5′ TTCTAATACGACTCACTATAgagtccgag
cagaagaagaaGTTTTAGAGCTAGA 3′
Mouse Fto: 5′ TTCTAATACGACTCACTATAgcatgaagcgcgtc
cagaccgGTTTTAGAGCTAGA 3′
After transcription, sgRNAs were puriﬁed by acidic phenol/chloroform
extraction and precipitated using 2.5 volumes of 100% ethanol. sgRNA integrity
was then assessed by denaturing urea polyacrylamide gel electrophoresis.
Cas9-sgRNA RNP electroporation procedure. Cas9-sgRNA RNP electroporation
was performed as described in the manufacturer’s protocol. Brieﬂy, 12 pmol of
recombinant Cas9 (EnGen Cas9 NLS, S. pyogenes; New England Biolabs; M0646T)
were incubated with 12 pmol of in vitro transcribed sgRNAs in the presence of
Resuspension Buffer R (Neon Transfection System; ThermoFisher Scientiﬁc;
MPK1025) for 20 min at room temperature. After this, 1 × 105 cells resuspended in
5 µl of resuspension buffer R (for HEK293T cells) or resuspension buffer T (for
primary mouse BM cells) are added to the Cas9-sgRNA mix and the whole mixture
electroporated with the following settings:
-1700 V, 20 ms, 1 pulse (HEK293T cells)
-1350 V, 10 ms, 4 pulses (mouse BM cells)
-1680 V, 20 ms, 1 pulse (mouse BM cells)
Upon electroporation, cells were incubated in their corresponding medium
(DMEM complemented with 10% FCS for HEK293T cells and DMEM
complemented with 10% FCS and 20% L929 supernatant containing MCSF for
24 h before extracting their genomic DNA to assess genome editing.
Combination of Nanoblades with ssDNA and dsDNA. Nanoblades programmed
to target the AUG codon of DDX3 were resuspended in PBS 2% FBS and combined
with ssDNA donor repair template (see the sequence of “Flag-DDX3 primer”
below) at a ﬁnal concentration of 0.3, 1.3 or 6.7 µM in 30 µl of PBS supplemented
with polybrene (Sigma) at 4 µg/ml. Complexes were let 15 min on ice before
addition to 7 × 104 HEK293T cells plated 6 h before in 400 µl of complete medium
supplemented with polybrene (4 µg/ml). 24 h latter, transduction medium was
supplemented with 1 ml of fresh medium (10% FCS) and cells were passed the day
after into six-well plates for ampliﬁcation. Cells were ampliﬁed in 10 cm dishes and
passed six times during 3 weeks before extraction of proteins and genomic DNAs.
Sequence of the Flag-DDX3 primer (HPLC-puriﬁed):
5′-ACTCGCTTAGCAGCGGAAGACTCCGagTTCTCGGTA
CTCTTCAGGGATGGA
CTACAAGGACGACGATGACAAGagTCATGTGGCAGTG
GAAAATGCGCTCGGGCTGGACCAGCAGGTGA-3’
DDX3 ampliﬁcation was performed using the following primers: DDX3-
Forward 5′-CTTCGCGGTGGAACAAACAC-3′ and DDX3-Reverse1 5′-
CGCCATTAGCCAGGTTAGGT-3′ for the “Insertion PCR assay” and Flag-
Forward 5′-GACTACAAGG
ACGACGATGACAAG-3′ and DDX3-Reverse2 5′-CGCCATTA
GCCAGGTTAGGT-3′ for the “Orientation PCR assay”. PCR conditions were
performed as follows: 94 °C 5min, followed by three cycles (94 °C 30 s, 64 °C 30 s,
72 °C 30 s), followed by 25 cycles (94 °C 30 s, 57 °C 30 s, 72 °C 30 s), followed by 5min
at 72 °C.
dsDNA (AAVS1): 10 µl of concentrated Nanoblades were complexed with
650 ng of dsDNA in a total volume of 30 µl of PBS with polybrene at a ﬁnal
concentration of 4 µg/ml. After 15 min of incubation on ice, complexes were used
to transduce 1 × 105 HEK293T cells in a 24-well plate containing medium
supplemented with polybrene (4 µg/ml). Two days latter cells were reseeded in a
10 cm dish before puromycin selection (0.5 µg/ml). Single-cell-derived clones were
next isolated and cultivated in a 12-well plates before PCR analysis performed on
genomic DNAs (500 ng).
Primers used to assess the presence of the puromycin cassette are:
Puromycin-forward 1: 5′-GGCAGGTCCTGCTTTCTCTGAC-3′
Puromycin-reverse 1: 5′-GATCCAGATCTGGTGTGGCGCG
TGGCGGGGTAG-3′
Followed by a nested-PCR using the following primers:
Puromycin-forward 2: 5′-GATATACGCGTCCCAGGGCCGG
TTAATGTGGCTC-3′
Puromycin-reverse 1: 5′-GATCCAGATCTGGTGTGGCGCG
TGGCGGGGTAG-3′
Primers used to assess correct integration of the cassette at the AAVS1 locus
are:
AAVS1-forward: 5′-CGGAACTCTGCCCTCTAACGCTG-3′
Puromycin reverse 2: 5′-GATCCAGATCTGGTGTGGCGCG
TGGCGGGGTAG-3′
Followed by a nested-PCR using the following primers:
AAVS1-forward: 5′-GGCAGGTCCTGCTTTCTCTGAC-3′
Puromycin reverse 3: 5′-CACCGTGGGCTTGTACTCGGT
CAT-3′
Flag-immunoprecipitation and western-blotting. For Flag-immunoprecipitation,
5 × 106 cells were lysed in 500 µl of lysis buffer (NaCl 300 mM, MgCl2 6 mM,
Tris–HCl 15 mM, 0.5% NP40). 250 µl of the cell lysate (1 mg of total proteins) was
incubated with 40 µl of M2-antiFlag magnetic beads (Sigma M8823) equilibrated in
TBS. After incubation for 2 h at 4 °C, beads were washed four times in lysis buffer
and proteins eluted in 60 µl of TBS supplemented with Flag-peptide (120 µg/ml
ﬁnal) for 2 h at 4 °C. The supernatant (without beads) was then collected and used
for western-blot analyses.
Western-blotting against Flag-DDX3 and endogenous DDX3 was performed
using the following antibodies: anti-DDX3 (rabbit, Sigma 19B4, 1/1000 dilution),
Flag-M2 Antibody (mouse, Sigma F3165, 1/2000 dilution), and actin antibody
(mouse, Sigma A1978, 1/10,000 dilution). The uncropped images for
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Supplementary Figs. 1a, 2d, 3d and 2b–d, 3a, 4d are provided in Supplementary
Fig. 7.
T7 endonuclease assay. Genomic DNA was extracted from VLP-treated cells
using the Nucleospin gDNA extraction kit (Macherey-Nagel). 150 ng of genomic
DNA was then used for PCR ampliﬁcation. PCR products were diluted by a factor
2 and complemented with Buffer 2 (New England Biolabs) to a ﬁnal concentration
of 1×. Diluted PCR amplicons were then heat denatured at 95 °C and cooled down
to 20 °C with a 0.1 °C/s ramp. Heteroduplexes were incubated for 30 min at 37 °C
in presence of 10 units of T7 Endonuclease I (NEB). Samples were ﬁnally run on a
2.5% agarose gel or on a BioAnalyzer chip (Agilent) to assess editing efﬁciency.
Reverse-transcription and quantitative PCR. Total RNAs were extracted using
TriPure Isolation Reagent (Roche, 11667165001) following the manufacturer’s
instructions. 1.5 µg of total RNA was treated with DNase and reverse-transcribed
using Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Scientiﬁc,
K1672) following the manufacturer’s instructions. qPCR experiments were per-
formed on a LightCycler 480 (ROCHE) in technical triplicates in 10 µl reaction
volume as follows: 5 µl of 2X SYBR qPCR Premix Ex Taq (Tli RNaseH Plus)
(TAKARA, TAKRR420W); forward and reverse primers (0.5 µM each ﬁnal); 7.5 ng
of cDNA.
Immunoﬂuorescence and imaging. Cells were ﬁxed in 1X PBS supplemented with
4% of paraformaldehyde (PFA) for 20 min, washed three times with 1X PBS and
permeabilized with 0.5% Triton X-100 for 4.5 min. Cells were incubated with
primary antibodies overnight at 4 °C. Primary antibodies used are: rabbit yH2AX
(1:1000; Abcam 81299) and mouse RNA pol I RPA194 (1:500; Santacruz sc48385).
Cells were washed three times in 1X PBS, followed by incubation of the secondary
antibodies conjugated to Alexa 488 or 594 used at a 1:1000 dilution (Life Tech-
nologies) for 1 h at room temperature. After three 1X PBS washes, nucleus were
stained with Hoechst 33342 at 1 μg/ml for 5 min. The coverslips were mounted in
Citiﬂuor medium (AF1, Citiﬂuor, London, UK). Cells were observed under a Leica
DM6000. At least 100 cells were counted in each indicated experiment. Averages
and standard deviation values were obtained from three independent biological
replicates.
Flow cytometry analysis of CD81 expression. 1 × 106 HepG2 or HEK293T cells
were detached from the cell culture plate using Accutase (Stemcell technologies
#07920) and washed twice in PBS+ 2%BSA. Cells were then incubated in 100 µl of
PBS+ 2%BSA+Anti-CD81 (BD Biosciences #555675, clone JS-81, 1/200 dilution)
for 30 min at 4 °C. Cells were then washed three times in PBS+ 2% BSA and
incubated in 100 µl of PBS+ 2 %BSA+ anti-mouse FITC (Biolegend # 406001, 1/
2000 dilution) for 30 min at 4 °C in the dark. Cells were then washed three times in
PBS+ 2%BSA and ﬁxed with 4% of paraformaldehyde (PFA) for 15 min and
washed in PBS+ 2%BSA before ﬂow cytometry analysis on a BD FACSCanto II.
Northern-blot of sgRNAs. 2 µg of total RNA extracted from Nanoblades or
Nanoblade-producing cells were run on a 10% acrylamide, 8 M Urea, 0.5X TBE gel
for 1 h at 35W. RNAs were then transferred onto a Nitrocellulose membrane
(Hybond Amersham) by semi-dry transfert for 1 h at 300 mA in 0.5X TBE. The
membrane was UV-irradiated for 1 min using a stratalinker 1800 and then baked at
80 °C for 30 min. The membrane was then incubated in 50 ml of Church buffer
(125 mM Na2HPO4, 0.085% phosphoric acid, 1 mM EDTA, 7% SDS, 1% BSA) and
washed twice in 10 ml of Church buffer. The 5′ P32-labeled (1 × 107 cpm total) and
heat-denatured ssDNA probe directed against the constant sequence of the
guideRNA (sequence of the sgRNA antisense probe: 5′GCACCGACTCGGTGCCA
CTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTA
GCTCTA3′) was diluted in 10 ml of Church buffer and incubated with the
membrane overnight at 37 °C. The membrane was washed four times in 50 ml of
wash buffer (1X SSC+ 0.1% SDS) before proceeding to phosphorimaging.
Transmission electron microscopy (TEM) and mass spectrometry (MS).
Nanoblades programmed to target the YFP were prepared and processed for TEM
and MS as previously described46. Brieﬂy, Nanoblades were produced from
transfected Gesicles Producer 293T cells plated at 5 × 106 cells/10 cm plate 24 h
before transfection with the JetPrime reagent (Polyplus) and supernatants were
collected from producer cells after 40 h, passed through a 0.45 µm ﬁlter and con-
centrated 100-fold by overnight centrifugation at 3800 × g. This preparation was
next laid overlaid on a continuous optiprep gradient and ultracentrifuged to obtain
density fractions. Fractions containing Nanoblades were next pooled and cen-
trifuged overnight at 3800 × g before PBS resuspension to obtain a 6000×-con-
centrated sample.
For electron microscopy, after a ﬂash-ﬁxation in glutaraldehyde, staining was
ampliﬁed using the R-Gent Kit (Biovalley, Marne-la-Vallee, France) before the
negative coloration (phosphotungstic acid 2%). Specimen were observed under a
JEM-1400 microscope (Jeol, Tokyo, Japan) coupled with the Orius-600 camera
(Gatan, Pleasanton, CA).
High-troughput sequencing of RNAs extracted from Nanoblades. Total RNA
was extracted from puriﬁed Nanoblades programmed to target the YFP using
Trizol. RNAs were then fragmented to 100nt and used as input for the preparation
of cDNA libraries following the protocol described in ref. 47. Brieﬂy, RNA frag-
ments with a 3′-OH were ligated to a preadenylated DNA adaptor. Following this,
ligated RNAs were reverse transcribed with Superscript III (Invitrogen) with a
barcoded reverse-transcription primer that anneals to the preadenylated adaptor.
After reverse transcription, cDNAs were resolved in a denaturing gel (10% acry-
lamide and 8M urea) for 1 h and 45 min at 35W. Gel-puriﬁed cDNAs were then
circularized with CircLigase I (Epicentre) and PCR-ampliﬁed with Illumina’s
paired-end primers 1.0 and 2.0.
Analysis of high-troughput sequencing data was performed as previously
described48. Brieﬂy, reads were split with respect to their 5′-barcode sequence.
After this, 5′-barcode and 3′-adaptor sequences were removed from reads. Reads
were mapped to a custom set of sequences including 18S, 28S, 45S, 5S, and 5.8S
rRNA, tRNAs, the sgRNA directed against the GFP sequence and all transcripts
coding for Nanoblades components (Envelopes, Gag and Pol, Cas9) using
Bowtie49. Reads that failed to map to this custom set of sequences were next
aligned to University of California, Santa Cruz (UCSC) human hg18 assembly
using TopHat250. Read counts on all transcripts of interest were obtained using the
HTSeq count package51.
High-throughput sequencing of Emx1 On-target and Off-target loci. Genomic
DNA was extracted from Nanoblades-treated cells using the Nucleospin gDNA
extraction kit (Macherey-Nagel). 150 ng of genomic DNA was then used for PCR
ampliﬁcation using primers speciﬁc for the EMX1 On-target locus (EMX1-Forward
5′-ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGTTCCAGAACCGG
AGGACAAAGTAC-3′ and EMX1-Reverse 5′-GTGACTGGAGTCCTCTCTAT
GGGCAGTCGGTGAAGCCCATTGCTTGTCCCTCTGTCAATG-3′) and the
previously described Off-target locus in the intron of MFAP1 (MFAP1-Forward 5′-
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCCATCACGGCCTTTG
CAAATAGAGCCC-3′ and MFAP1-Reverse 5′-GTGACTGGAGTCCTCTCTA
TGGGCAGTCGGTGACAGAGGGAACTACAAGAATGCCTGAGC-3′) bear-
ing adapters sequencing for Illumina’s Miseq platform. Obtained PCR products
were puriﬁed and PCR ampliﬁed with a second set of primers bearing speciﬁc
barcodes for multiplex sequencing. Final PCR products were sequenced on the
Miseq platform using a custom sequencing primer (Miseq-Custom 1: 5′
ATCACCGACTGCCCATAGAGAGGACTCCAGTCAC 3′) and a custom index
sequencing primer (Miseq-Custom 2: 5′ GTGACTGGAGTCCTCTCTATGGGC
AGTCGGTGAT 3′).
Animal experimentation. All animal experiments were approved by a local ethics
committee of the Université de Lyon (CECCAPP, registered as CEEA015 by the
French ministry of research) and subsequently authorized by the French ministry
of research (APAFIS#8154-20161l2814462837 v2 for the generation of transgenic
animals and C 69 123 0303 for the usage of Nanoblades in vivo). All procedures
were in accordance with the European Community Council Directives of Sep-
tember 22, 2010 (2010/63/EU) regarding the protection of animals used for sci-
entiﬁc purposes.
Mouse oocyte injection. Four or ﬁve weeks old FVB/NRj female mice (Janvier
Labs, France) were superovulated by intraperitoneal (i.p.) administration of 5 IU of
pregnant mare serum gonadotropin (PMSG, Alcyon, France), followed by an
additional i.p. injection of 5 IU human chorion gonadotropin 48 h later (hCG,
Alcyon, France). Superovulated females were mated with B6D2F1 adult males
(1 male/2 females) and euthanatized at 0.5 day post coitum (usually between 10
and 11 a.m.). Oviduct were dissected, and the ampulla nicked to release zygotes
associated with surrounding cumulus cells into a 200 µl droplet of hyaluronidase
(Sigma) in M2 solution (300 µg/ml, Sigma) under a stereomicroscope (Olympus
SZX9). Zygotes were incubated for 1 min at room temperature and passed with a
mouth pipette through three washes of M2 medium to remove cumulus cells.
Zygotes were kept in M16 medium (Sigma) in a water jacketed CO2 incubator
(5% CO2, 37 °C) until microinjection with Nanoblades. Micro-injection were
carried-out under a stereomicroscope (Olympus SZX9) using a FemtoJet 4i
(Eppendorf) microinjecter. Brieﬂy, 1 pl of Nanoblades were injected in the peri-
vitelline space of oocytes. Zygotes were then transferred into M16 medium and
kept overnight in incubator. The embryos that reached the two-cell stage were
transferred into the oviduct of B6CBAF1 (Charles River, France) pseudopregnant
females (15–20 embryos per female).
Retro-orbital injection of Nanoblades. All experiments were performed in
accordance with the European Union guidelines for approval of the protocols by
the local ethics committee (Authorization Agreement C2EA 15, “Comité Rhône-
Alpes d’Ethique pour l’Expérimentation Animale”, Lyon, France). The highly
Immunosuppressed NOD FRG mice (Fah-/-/Rag2-/-/Il2rg-/-) (Yecuris cooration),
deﬁcient for T-cell, B-cell, and NK-cell are maintained in pathogen-free facility.
Retro-orbital injection (SRO) were performed under isoﬂurane anesthésia.
Genomic DNA from each mouse (treated either by control or Hpd targeting
Nanoblades) was extracted from three distinct liver lobes and pooled together.
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Following this, a two-step PCR was performed on 300 ng of gDNA template, the
ﬁrst PCR using primers Hpd-Forward 1: 5′-CTTAGGAGGTTAGCCAAAGATG
GGAG-3′ and Hpd-Reverse 1: 5′-TCTAGTCTCTATCCAGGGCTCCAGCC-3′ to
amplify the Hpd gene (94 °C 5min, 3 cycles 94 °C, 64 °C, 72 °C, and 20 cycles 94 °C,
58 °C, 72 °C, 5 min 72 °C). The second nested-PCR used primers Hpd-Forward 2:
5′-GAACTGGGATTGGCTAGTGCG-3′ and Hpd_Reverse 2: 5′-CACCCAG
CACCACCTATAGAAACTC-3′ (94 °C 5min, 3 cycles 94 °C, 64 °C, 72 °C and
30 cycles 94 °C, 57 °C, 72 °C, 5 min 72 °C). Amplicons were next analyzed by T7-
endonuclease assay as described.
Raw data ﬁles. Uncropped scans of ethidium bromide gels and western-blotting
ﬁgures are displayed in Supplementary Figure 7.
Data availability
Gene Expression Omnibus: GSE107035. The following plasmids will be available
from Addgene: Gag::Cas9 fusion (BIC-Gag-CAS9, Plasmid ID: 119942), the Gag::
Cas9-VPR fusion (BICstim-Gag-dCAS9-VPR, Plasmid ID: 120922) and the Gag::
Cre fusion (GAG-CRErec, Plasmid ID: 119971).
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